Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment.
about
Current understanding of interactions between nanoparticles and the immune systemNanomilling of Drugs for Bioavailability Enhancement: A Holistic Formulation-Process Perspective.Anti-HIV-1 nanotherapeutics: promises and challenges for the futureNanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV TransmissionThe potential of HIV-1 nanotherapeutics: from in vitro studies to clinical trialsActivation of latent HIV using drug-loaded nanoparticlesHumanized mice recapitulate key features of HIV-1 infection: a novel concept using long-acting anti-retroviral drugs for treating HIV-1Towards a rational design of solid drug nanoparticles with optimised pharmacological properties.Implementation challenges for long-acting antivirals as treatment.A review of nanotechnological approaches for the prophylaxis of HIV/AIDS.NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery.Combination antiretroviral drugs in PLGA nanoparticle for HIV-1.Formulation, characterization and pharmacokinetics of praziquantel-loaded hydrogenated castor oil solid lipid nanoparticles.HIV-1 neuroimmunity in the era of antiretroviral therapy.Emerging nanotechnology approaches for HIV/AIDS treatment and prevention.Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulationE138A in HIV-1 reverse transcriptase is more common in subtype C than B: implications for rilpivirine use in resource-limited settings.The emerging profile of cross-resistance among the nonnucleoside HIV-1 reverse transcriptase inhibitors.Optimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling.Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages.Type and composition of surfactants mediating gene transfection of polyethylenimine-coated liposomes.Preparation and evaluation of quercetin-loaded lecithin-chitosan nanoparticles for topical delivery.The clinical role and cost-effectiveness of long-acting antiretroviral therapyDevelopment and validation of a simple and isocratic reversed-phase HPLC method for the determination of rilpivirine from tablets, nanoparticles and HeLa cell lysates.Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings.Nanotechnology and the treatment of HIV infection.pH-responsive nanoparticles releasing tenofovir intended for the prevention of HIV transmissionLong-acting slow effective release antiretroviral therapy.Distinct Pharmacodynamic Activity of Rilpivirine in Ectocervical and Colonic Explant Tissue.A long-acting formulation of the integrase inhibitor raltegravir protects humanized BLT mice from repeated high-dose vaginal HIV challenges.Next-generation oral preexposure prophylaxis: beyond tenofovirLack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744.Human biotransformation of the nonnucleoside reverse transcriptase inhibitor rilpivirine and a cross-species metabolism comparison.Long-acting injectable antiretrovirals for HIV treatment and preventionNanoART, neuroAIDS and CNS drug delivery.Pre-exposure prophylaxis for HIV infection: how antiretroviral pharmacology helps to monitor and improve adherenceA mature macrophage is a principal HIV-1 cellular reservoir in humanized mice after treatment with long acting antiretroviral therapyLong-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients.A mini review of nanosuspensions development.Recent advancements in mechanical reduction methods: particulate systems.
P2860
Q26345204-C2F60F4C-1E44-42AD-B77F-E96DC1F4EAC9Q26746912-E4F4E5DE-D569-405E-B2EB-075ACBB83026Q26828464-A2552885-5C25-48BF-8500-4FEA466DF85AQ27318354-95E26733-81F5-4BFF-8976-0E589B37AC5BQ28087336-8CD0319E-34D7-49E5-8A83-C44ADAC6F0E0Q28477657-0AF2D8D3-C77F-48F4-9BB5-A756B1FED9E6Q28728527-B86AA920-15EF-461B-A3A3-4897E5FBE8F4Q30372133-A78FFD55-1E91-49EE-8741-AAD094E380F8Q30375397-C0F59478-A49E-4BF4-9384-8E491181FDB1Q30431343-7B314CC3-2A27-48DA-AEF3-E002DBEFD633Q30493643-013D2065-0F05-49CF-93F4-AA7F71D03C56Q33517859-4EDDDA22-8B6C-4AC2-97CA-301CD67D975FQ33642023-75F5EB6B-0B8D-4D91-B550-7844E47DA75BQ33733529-E6F9C28E-624B-4757-9B59-1B661CF03AA0Q33819656-DC0406CF-94BA-4DDC-B10C-8EDB91E3826DQ33826308-2C82D51C-8FF7-4D4F-B68B-64E5D3F9D159Q33873990-C30E538C-0501-4695-904B-4741388CDC0FQ34102246-70DDD0B0-DEE5-48BD-BBD1-D86C874521C4Q34571360-D38D9697-56AA-441D-AAF7-F08921F600F7Q34728884-44869DB0-A705-4974-9DB6-9B834A17B3F4Q35071617-E24758CA-CD17-4E97-BBD2-FE036CACF7DEQ35179026-C7BE8556-63DD-4872-AF8C-42431146FEB2Q35197271-36D205B9-2416-4E66-919A-D6259A70974EQ35314702-52AC5938-9062-4230-BD80-6D83488FA444Q35557326-74402739-EF7E-4236-9AAF-DB99F9CD169EQ35943647-49EE8EE3-0941-4B48-AD5B-A43E470D578CQ36032459-DAA74DE2-9A01-485C-AEEB-CB109743915DQ36262152-EAC5DC08-BD2C-4823-B751-43C570CAD485Q36888077-CC27045B-F295-4E8A-960F-5BFADFA966B2Q36901505-0ECEEFC1-8F05-47AB-AD3C-EDA773412EF3Q37067126-D51912BE-FAE2-4ECF-A17E-F8E440529F9EQ37263531-F02F392F-6E42-4CA2-8C6B-14E63175F7D2Q37263885-2CAC07E5-415D-4A89-92CE-9241EF723677Q37272776-C005BEFF-AE9C-44C0-AD76-76CC82EB3981Q37538776-7F4D2E53-22B3-4018-86F6-2FBB5DC60A16Q37637073-2BC72AD1-C422-43E2-B580-132F690DD72BQ37692595-2A221A09-C3E2-4830-BCCE-4215911FD388Q37704651-FD61538C-7047-4FEF-9A57-BAE5A1A1F228Q37970772-D370B641-C40C-44DA-837E-0E83C1866AA3Q38132471-375DA767-6134-4A7E-A27C-D3593318B016
P2860
Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մարտին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Development of a long-acting i ...... ne (TMC278) for HIV treatment.
@ast
Development of a long-acting i ...... ne (TMC278) for HIV treatment.
@en
type
label
Development of a long-acting i ...... ne (TMC278) for HIV treatment.
@ast
Development of a long-acting i ...... ne (TMC278) for HIV treatment.
@en
prefLabel
Development of a long-acting i ...... ne (TMC278) for HIV treatment.
@ast
Development of a long-acting i ...... ne (TMC278) for HIV treatment.
@en
P2093
P1476
Development of a long-acting i ...... ne (TMC278) for HIV treatment.
@en
P2093
Alfons Wouters
Esther Basstanie
Fred Stappers
Gerben van 't Klooster
Guenter Kraus
Jan Rosier
Koen Iterbeke
Laurent Schueller
Lieven Baert
Marc François
P304
P356
10.1016/J.EJPB.2009.03.006
P407
P577
2009-03-27T00:00:00Z